<DOC>
	<DOCNO>NCT01966549</DOCNO>
	<brief_summary>The purpose study evaluate effect CNTO6785 compare placebo participant moderate severe Chronic Obstructive Pulmonary Disease .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Safety CNTO6785 Patients With Moderate Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This multi-center , randomize ( study medication assign chance ) , placebo-controlled ( effect study medication compare effect placebo [ inactive substance ] ) , double-blind ( neither physician participant know treatment participant receives ) , parallel-group study ( group participant treat time ) . This study consist 3 phase : screening phase ( within 3 week prior start study medication ) , treatment phase ( 12 week ) , follow-up phase ( 12 week last administration study medication ) . Approximately 170 participant enrol study receive CNTO6785 placebo 1:1 ratio . Safety evaluate assessment adverse event , vital sign , 12-lead electrocardiogram , physical examination , early detection active tuberculosis , clinical laboratory test monitor throughout study . The total duration study participation participant 30 week .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion criterion : Moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) ( Grade II Grade III accord GOLD Guidelines ) chronic bronchitis ( sputum production day least 12 week per year least 2 successive year ) screen Persistent COPD symptom require repeat ( great 1 ) 'as need ' use short act rescue medication within 4 week prior screen Had least 2 COPD exacerbation require antibiotic and/or systemic corticosteroid past 2 year OR able spontaneously produce adequate sputum sample within 3 6 week prior start study medication Be current exsmoker smoke history least 10 pack year screen Meet tuberculosis ( TB ) screen criterion : history latent active TB , sign symptom suggestive active TB , recent ( within 3 month ) close contact person active TB , evidence current , active TB old , inactive TB Exclusion criterion : Pulmonary disease , asthma , clinically significant bronchiectasis , cystic fibrosis , sarcoidosis , interstitial lung disorder , moderate severe sleep apnea , pulmonary hypertension screening Has ever experience lifethreatening COPD , lung lobectomy , lung cancer surgery , lung volume reduction , lung transplant Requires oxygen therapy daily basis ( great 12 hours/day ) chronic hypoxemia ( inadequate level oxygen blood ) screening Has receive live , attenuated viral bacterial vaccine within 3 month prior screen expect receive live attenuate vaccination study 6 month last administration study medication Positive serology human immunodeficiency virus 1 2 , hepatitis B virus , hepatitis C virus</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pulmonary Disease , Chronic Obstructive</keyword>
	<keyword>Moderate Severe Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>CNTO 6785</keyword>
	<keyword>Placebo</keyword>
</DOC>